GHRP-2

Quick Facts

Introduction

GHRP-2 (growth-hormone-releasing peptide-2, also known as pralmorelin) is a synthetic hexapeptide that belongs to the growth-hormone-releasing peptide (GHRP) family — a class of small molecules that mimic the endogenous hormone ghrelin at the pituitary. In research settings it is studied as a tool for probing the GH/IGF-1 axis, and it is frequently examined alongside GHRP-6, Ipamorelin, and Hexarelin, all of which share the broad theme of stimulating endogenous growth-hormone release.

What distinguishes the GHRP class from the GHRH analogues — compounds such as CJC-1295 and Sermorelin — is the receptor they engage. GHRPs act on the growth-hormone secretagogue receptor (GHS-R1a), the same receptor used by ghrelin, rather than on the GHRH receptor. Because the two receptor systems are distinct but complementary, researchers often study a GHRP and a GHRH analogue together to probe coordinated growth-hormone secretion.

This profile covers what GHRP-2 is, its molecular characteristics, its GHS-receptor mechanism, the growth-hormone and appetite research it appears in, and how it compares with related secretagogues. Related compounds are catalogued in the peptide database, and the broader class is summarized in the research library.

What is GHRP-2?

GHRP-2 is a synthetic ghrelin-mimetic hexapeptide developed as part of the early effort to design small peptides that could stimulate growth-hormone release. It descends conceptually from the original GHRP-6 scaffold but carries amino-acid modifications that researchers have associated with a more potent, somewhat more selective secretagogue profile.

Unlike native ghrelin, which is a 28-residue acylated peptide, GHRP-2 condenses the essential receptor-activating chemistry into just six residues built largely from D-amino acids and unnatural residues (such as D-2-naphthylalanine). These non-natural building blocks slow enzymatic degradation, giving the molecule a more practical stability profile for research than the native hormone.

Because GHRP-2 works upstream of growth hormone — prompting the pituitary to release its own stored hormone rather than supplying exogenous GH — researchers describe the resulting secretion as preserving the pulsatile pattern of the natural axis. This is the same conceptual feature emphasized across the secretagogue family.

Molecular and structural characteristics

GHRP-2 has the sequence D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH₂, a C-terminally amidated hexapeptide. The incorporation of D-configured and unnatural residues is the structural feature most associated with its resistance to peptidases relative to all-L natural peptides, while the aromatic residues (naphthylalanine, tryptophan, phenylalanine) are central to its engagement of the GHS receptor.

Its small size and well-defined sequence make GHRP-2 a convenient, reproducible research tool. The amidated C-terminus and the bulky aromatic side chains together define the pharmacophore that the GHS-R1a recognizes.

Mechanism of action

GHRP-2 acts as an agonist at the growth-hormone secretagogue receptor (GHS-R1a), a G-protein-coupled receptor expressed on the somatotroph cells of the anterior pituitary and in the hypothalamus. Receptor activation engages the Gq/phospholipase-C pathway, raising intracellular calcium and triggering the release of stored growth hormone.

Because the GHS receptor is distinct from the GHRH receptor, GHRP-2 is studied for its ability to act synergistically with GHRH analogues. The two pathways converge on the somatotroph through different intracellular routes, so combining a GHRP with a GHRH analogue is reported to produce a larger, coordinated growth-hormone pulse than either compound alone — a recurring theme in secretagogue research.

GHRP-2 also amplifies growth-hormone output partly by opposing somatostatin, the inhibitory hypothalamic signal that normally restrains GH release. Through ghrelin-receptor signaling it additionally has a reported, comparatively modest effect on appetite, reflecting the receptor's overlap with the physiological ghrelin system. The downstream consequence of stimulated GH release is elevation of hepatic insulin-like growth factor 1 (IGF-1).

• GHS-R1a (ghrelin-receptor) agonism on pituitary somatotrophs.
• Gq/phospholipase-C signaling and intracellular calcium rise.
• Stimulation of pulsatile growth-hormone release.
• Partial opposition of somatostatin tone.
• Downstream elevation of IGF-1 and modest appetite signaling.

Growth-hormone axis research

The core research context for GHRP-2 is the GH/IGF-1 axis. In study populations and preclinical models, GHRP-2 administration has been associated with marked, dose-related increases in circulating growth hormone, and it has been examined as a provocative agent in growth-hormone stimulation testing. Its potency is one of the features that distinguishes it within the GHRP class.

Researchers frequently contrast GHRP-2 with the gentler, more selective profile of Ipamorelin, which is reported to release growth hormone with minimal effect on cortisol and prolactin. GHRP-2 sits between the older GHRP-6 and the highly potent Hexarelin in the family lineage, and is studied in the same conceptual conversation as GHRH analogues such as Tesamorelin and CJC-1295.

Appetite and ghrelin-system research

Because GHRP-2 engages the ghrelin receptor, it is also studied in the context of appetite and energy-balance signaling. Ghrelin is sometimes called the 'hunger hormone,' and ghrelin-receptor agonists are examined in research models for their reported orexigenic (appetite-stimulating) effects. GHRP-2's appetite effect is generally described as more modest than that of GHRP-6, which is the family member most strongly associated with hunger stimulation.

This dual character — a growth-hormone secretagogue that also touches the appetite axis — is what makes the GHRP class scientifically distinct from pure GHRH analogues. Researchers studying GHRP-2 therefore consider both the somatotropic (GH-releasing) and the metabolic/appetite dimensions of GHS-receptor activation.

Comparison: GHRP-2 vs GHRP-6 vs Ipamorelin

GHRP-2 is most often compared with the other ghrelin-mimetic secretagogues. GHRP-6 is the original of the family and is associated with the strongest appetite effect; Ipamorelin is a later, more selective pentapeptide reported to spare cortisol and prolactin. All three act through the GHS receptor but differ in potency and side-signal profile.

Researchers frequently pair a GHRP with a GHRH analogue because their receptors are complementary — for example studying GHRP-2 together with CJC-1295. Full entries for each compound are in the peptide database.

Half-life and pharmacokinetic considerations

GHRP-2 is a short-acting peptide. Its growth-hormone-releasing effect is reported to be rapid in onset and transient, with a plasma half-life on the order of tens of minutes — consistent with its role as a provocative stimulus that produces a discrete GH pulse rather than a sustained elevation.

This short duration is the reason GHRP-2 is studied as a pulsatile secretagogue: each exposure prompts a defined burst of growth-hormone release. The D-amino-acid and unnatural-residue content extends its stability relative to native ghrelin, but it remains far shorter-acting than long-duration GHRH analogues such as the DAC form of CJC-1295.

Reconstitution and handling considerations

GHRP-2 is supplied as a lyophilized powder and reconstituted with sterile or bacteriostatic water, added slowly down the vial wall and swirled gently rather than shaken to protect the peptide. The reconstituted solution should be clear; cloudiness or particulates indicate it should be discarded.

Working concentration is selected so research volumes are convenient and reproducible. The reconstitution calculator and reconstitution guide describe the general method.

• Add diluent slowly; swirl gently rather than shaking.
• Confirm the solution is clear before use.
• Protect from light and excess warmth.
• Avoid repeated freeze–thaw cycles of reconstituted material.

Storage considerations

Lyophilized GHRP-2 is most stable frozen at −20 °C, kept dry and away from light. Once reconstituted, it is refrigerated at 2–8 °C and used within a limited window; aliquoting reduces how often a given solution is cycled.

Research limitations

GHRP-2 is a research compound. Although the GHS-receptor biology is comparatively well characterized, much GHRP-2-specific data come from short-term studies, provocative-testing protocols, or preclinical models, and reported effects are dose-, route-, and design-dependent. Tolerance of the growth-hormone response with sustained exposure, and the metabolic implications of chronic GHS-receptor activation, remain active research questions. It is described here strictly for research reference.

• Much data come from short-term or provocative-testing contexts.
• Reported effects are dose-, route-, and design-dependent.
• Long-term consequences of sustained GHS-receptor activation are not established.
• It is not an approved therapy and is described solely for research reference.

Frequently Asked Questions

Related Research Profiles

References

1. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. 1999;402(6762):656-660.Source
2. Howard AD, et al. A receptor in pituitary and hypothalamus that functions in growth hormone release. Science. 1996;273(5277):974-977.Source
3. Bowers CY. Growth hormone-releasing peptide (GHRP). Cellular and Molecular Life Sciences. 1998.